Danaher Continues M&A Streak, Buying Life Sciences Firm Abcam for $5.7B
Abcam’s acquisition comes two months after its board announced the exploration of strategic alternatives that could include the sale of the company. Danaher beat out at least 20 companies that were potential buyers of the life sciences tools and antibody development firm.